Palo Alto – June 16, 2015 – Cooley advised Axovant Sciences Ltd. on its $362.3 million initial public offering. Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company now trades on the New York Stock Exchange under the symbol "AXON."
The Cooley corporate securities team advising Axovant included partners Frank Rahmani, John McKenna and Div Gupta, special counsel Brian Leaf and associates Ali Haggerty, Mark Ballantyne and Jason Saxe.
Support for the offering was provided by partner Marya Postner and associate Jennifer Raab (life sciences corporate partnering); partners Ivor Elrifi and Heidi Erlacher (intellectual property); partner Renee Deming (compensation and benefits); partner Seth Rafkin (employment and labor); partners Jeremy Naylor and Aaron Pomeroy (tax); and partners Wendy Goldstein and Natasha Leskovsek (health care and life sciences regulatory).
About Cooley LLP
High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters. Where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.